A new market forecast points to steady growth for microfluidic immunoassays, a class of tests that shrink complex lab chemistry onto tiny chips and cartridges. The report says the biggest demand in 2024 is expected to come from consumables such as cartridges and reagents, which together make up the bulk of routine testing. It also identifies cardiology as the leading application area, reflecting the continued burden of heart disease and the need for fast detection of cardiac markers in blood. At the same time, the analysis highlights a broader shift in diagnostics: moving from one-marker tests toward multiplex assays that can measure several disease signals at once. That matters because many conditions, especially cancer and infectious disease, are too biologically messy to be captured by a single molecule. Microfluidic systems aim to solve that by using very small fluid volumes, faster reactions, and compact device formats that can support point-of-care testing, meaning tests performed near the patient rather than in a central lab. In practical terms, the report suggests the market is being shaped by a mix of disease burden, clinical workflow needs, and the push to make advanced diagnostics quicker, smaller, and more informative.
What the market report says
The source divides the global microfluidic immunoassay market into consumables and systems. Consumables are the disposable parts used in testing, such as cartridges and reagents, while systems are the instruments that run the assay.
In 2024, consumables are expected to hold the largest share of the market at 69.6%. Within that group, microfluidic cartridges are projected to lead, which makes sense because every test run depends on a physical chip or cartridge loaded with a sample and the chemistry needed to detect targets.
Why cartridges dominate
A microfluidic cartridge works a bit like a miniature plumbing system etched into plastic or glass. It guides drops of blood or other samples through tiny channels, where antibodies can capture specific biomarkers, the measurable substances linked to disease.
The report ties cartridge demand to a wide range of use cases, including infectious disease testing, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine disorders. Because these cartridges are used both in clinical diagnostics and in research and development, they generate recurring demand that instrument sales alone cannot match.
Cardiology leads the application mix
Among applications, cardiology is expected to account for the largest share in 2024, at 53.5%. That reflects the central role of blood-based cardiac markers, molecules released after heart muscle injury, in diagnosing cardiovascular events.
The source connects this demand to the ongoing prevalence of heart disease. It cites the American Heart Association, which reports that more than 350,000 cardiac arrests occur outside the hospital each year in the U.S., underscoring the need for tests that can help clinicians identify heart-related problems quickly.
Why speed and small sample volumes matter
The appeal of microfluidic immunoassays is not just that they are small. Their real value is workflow: they can reduce sample and reagent use, shorten reaction times, and potentially move testing closer to the patient.
That is the promise of point-of-care, or POC, testing. Instead of sending a sample to a centralized lab and waiting hours or days, a clinic or emergency setting could get actionable information much sooner, which is especially important when decisions about infection treatment or cardiac care are time-sensitive.
The shift toward multiplex testing
One of the clearest trends in the report is the move toward multiple-analyte detection. An analyte is simply the thing a test measures, and in many diseases one analyte is not enough to capture what is happening in the body.
The source points out that a single molecular event may be inadequate for understanding diseases such as cancer. That is why multiplexed testing is gaining attention: it can detect several biomarkers in one run, while also reducing reagent consumption, improving sensitivity, and shortening the time needed for results.
Why infectious disease and oncology benefit
Multiplex testing is especially attractive in infectious disease. If several pathogens can produce similar symptoms, a one-target test may miss the real cause, while a culture-based lab method can take too long to guide early treatment.
In oncology, the logic is similar but biologically more complex. Cancer often involves overlapping pathways and mixed biomarker patterns, so a lab-on-chip device that reads several indicators at once could give clinicians a fuller picture than a single marker alone.
Industry direction and product strategy
The report notes that many companies are developing multiple-analyte tests to expand their lab-on-chip portfolios. A lab-on-chip device condenses laboratory steps onto a small platform, much like turning a benchtop lab into something closer to a smartphone-sized test engine.
This product strategy suggests companies see future growth not only in selling more tests, but in selling smarter ones. If a single cartridge can answer several clinical questions at once, it becomes more useful in busy care settings and more competitive in crowded diagnostics markets.
Why This Matters
Market reports do not prove that a technology will succeed clinically, but they do show where money, manufacturing, and product development are concentrating. Here, the signal is clear: the industry expects recurring demand for disposable test components, strong use in heart disease, and rising interest in assays that combine several readouts in one compact format.
For patients and clinicians, that could translate into faster answers from smaller samples and fewer fragmented tests. For health systems, it points to diagnostics that may fit better into emergency rooms, outpatient clinics, and decentralized care settings where speed can matter as much as analytical precision.
What to watch next
The next phase for this market will likely depend on how well companies turn technical advantages into clinical routine. Ease of use, manufacturing cost, regulatory progress, and proof that multiplex microfluidic tests improve real-world decisions will all shape adoption.
If those pieces come together, microfluidic immunoassays could become less of a niche tool and more of a standard testing format across cardiology, infectious disease, and cancer care. The current forecast suggests that the momentum is already there, and that the smallest parts of the system, especially cartridges, may continue to drive the biggest share of the business.